FR2836382B1 - NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS - Google Patents

NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS

Info

Publication number
FR2836382B1
FR2836382B1 FR0202559A FR0202559A FR2836382B1 FR 2836382 B1 FR2836382 B1 FR 2836382B1 FR 0202559 A FR0202559 A FR 0202559A FR 0202559 A FR0202559 A FR 0202559A FR 2836382 B1 FR2836382 B1 FR 2836382B1
Authority
FR
France
Prior art keywords
mal
conjugates
new
molecule
coupling agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0202559A
Other languages
French (fr)
Other versions
FR2836382A1 (en
Inventor
Xavier Lacoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0202559A priority Critical patent/FR2836382B1/en
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to EP03718910A priority patent/EP1478623B1/en
Priority to DE60336455T priority patent/DE60336455D1/en
Priority to AU2003222944A priority patent/AU2003222944A1/en
Priority to AT03718910T priority patent/ATE502919T1/en
Priority to PCT/FR2003/000619 priority patent/WO2003072546A1/en
Priority to US10/505,746 priority patent/US7132269B2/en
Publication of FR2836382A1 publication Critical patent/FR2836382A1/en
Application granted granted Critical
Publication of FR2836382B1 publication Critical patent/FR2836382B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Heterobifunctional functional coupling agents (I), comprising peptide derivatives containing at least one 8-amino-3,6-dioxa-octanoic acid unit and aminooxy and maleimide functional groups, are new. Heterobifunctional functional coupling agents of formula (I), comprising peptide derivatives containing at least one 8-amino-3,6-dioxa-octanoic acid unit and aminooxy and maleimide functional groups, are new. W = NH-(CH2)2O(CH2)2-OCH2CO; A = (W')p-CO-(CH2)u-Mal (a), (W')p-CO-CH-((CH2)rNH-(W')p-CO-(CH2)u-Mal)2 (b) or (W')p-CO-CH(-(CH2)rNH-(W')p-CO-CH(-(CH2)r-NH-(W')p-CO-(CH2)u-Mal)2)-(CH2)q-NH-(W')p-CH(-(CH2)r-NH-(W')p-CO-(CH2)u-Mal)2 (c); D = group (a), (b), (c) or CO-(CH2)u-Mal (d); Mal = maleimide; Y = group terminated by CONH2 and inert with respect to the remainder of the molecule; W' = COCH2O-(CH2)2O(CH2)2-NH; n = 0-3; m, o = 0-3; p = 1-4; q = 0-3; r = 2-5; s = 0 or 1; t = 1-7, and u = 2-10. Independent claims are also included for: (1) new activated intermediates (II) comprising (I) and a molecule (II') having at least one surface aldehyde and/or ketone function before conjugation; (2) new activated intermediates (III) comprising (I) and 1-8 (preferably 1-4) molecule(s) (III') having at least one surface thiol function before conjugation; and (3) new conjugates (IV) comprising (I) bonded to (II') and to 1-8 molecule(s) (III').
FR0202559A 2002-02-28 2002-02-28 NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS Expired - Fee Related FR2836382B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0202559A FR2836382B1 (en) 2002-02-28 2002-02-28 NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS
DE60336455T DE60336455D1 (en) 2002-02-28 2003-02-26 COUPLING AGENTS, THEIR ACTIVE INTERCONNECTIONS AND CONJUGATES, AND THE USE OF THESE CONJUGATES FOR DIAGNOSTIC PURPOSES
AU2003222944A AU2003222944A1 (en) 2002-02-28 2003-02-26 Novel coupling agents, the active intermediates and the conjugates thereof and the use of said conjugates in diagnostic methods
AT03718910T ATE502919T1 (en) 2002-02-28 2003-02-26 COUPLING MEANS, THEIR ACTIVE INTERMEDIATE COMPOUNDS AND CONJUGATES AND THE USE OF THESE CONJUGATES FOR DIAGNOSTIC PURPOSES
EP03718910A EP1478623B1 (en) 2002-02-28 2003-02-26 Novel coupling agents, the active intermediates and the conjugates thereof and the use of said conjugates in diagnostic methods
PCT/FR2003/000619 WO2003072546A1 (en) 2002-02-28 2003-02-26 Novel coupling agents, the active intermediates and the conjugates thereof and the use of said conjugates in diagnostic methods
US10/505,746 US7132269B2 (en) 2002-02-28 2003-02-26 Coupling agents, the active intermediates and the conjugates thereof and the use of said conjugates in diagnostic methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0202559A FR2836382B1 (en) 2002-02-28 2002-02-28 NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS

Publications (2)

Publication Number Publication Date
FR2836382A1 FR2836382A1 (en) 2003-08-29
FR2836382B1 true FR2836382B1 (en) 2004-08-13

Family

ID=27676179

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0202559A Expired - Fee Related FR2836382B1 (en) 2002-02-28 2002-02-28 NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS

Country Status (7)

Country Link
US (1) US7132269B2 (en)
EP (1) EP1478623B1 (en)
AT (1) ATE502919T1 (en)
AU (1) AU2003222944A1 (en)
DE (1) DE60336455D1 (en)
FR (1) FR2836382B1 (en)
WO (1) WO2003072546A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7356711B1 (en) 2002-05-30 2008-04-08 Microsoft Corporation Secure registration
FR2955111B1 (en) * 2010-01-12 2013-05-31 Biomerieux Sa PROCESS FOR THE PREPARATION OF POLYBIOTINYL COMPOUNDS
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
RS59459B1 (en) * 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use

Also Published As

Publication number Publication date
AU2003222944A1 (en) 2003-09-09
ATE502919T1 (en) 2011-04-15
US20050215771A1 (en) 2005-09-29
WO2003072546A1 (en) 2003-09-04
EP1478623B1 (en) 2011-03-23
EP1478623A1 (en) 2004-11-24
FR2836382A1 (en) 2003-08-29
US7132269B2 (en) 2006-11-07
DE60336455D1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
DE69910216D1 (en) CONJUGATES FOR TREATING INFLAMMATORY DISEASES AND ASSOCIATED TISSUE DAMAGE
CY1108007T1 (en) PHARMACEUTICAL COMPOSITIONS OF BOTULINE TOXIN
DE60006100D1 (en) LONG-LASTING INSULINOTROPE PEPTIDES
CY1109151T1 (en) DR4 ACCESSORIES AND THEIR USES
DE50014571D1 (en) VEHICLE PHARMAKA CONJUGATES
DE60224296D1 (en) HAIR CARE COMPOSITIONS
EP3118218A3 (en) Fusion proteins for blood-brain barrier delivery
DE1016419T1 (en) Non-invasive localization of a light-emitting conjugate in a mammal
DK0841949T3 (en) Use of saccharide conjugates
BR9508402A (en) Bonding Binder Fabric Factor Construction Pharmaceutical Composition Kit and Use of Bonding Binder
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
AR051512A1 (en) FUSION PROTEIN THAT INCLUDES A BH3 DOMAIN OF A "SOLO BH3" PROTEIN
DK0839026T3 (en) Micellar polyether block copolymer compositions for targeting biological agents
ATE335515T1 (en) MORPHOLINO IMAGING AND THERAPY
DE602006017667D1 (en) Cysteine-containing peptide-tag for site-specific conjugation of proteins
DK0858504T3 (en) Diagnostic remedies and treatments for periodontal diseases
DE69834133D1 (en) NYLON Oligomers
DK0450628T3 (en) Saccharide-mediated, water-soluble proteins
FR2836382B1 (en) NEW COUPLING AGENTS, THEIR CONJUGATES, AND THE USE OF SUCH CONJUGATES IN DIAGNOSTIC METHODS
ATE304709T1 (en) SUBSTANCES WITH BRANCHED LINKER MOLECULES
NO20033441L (en) Polymer conjugates of neubastine and their use
ATE272074T1 (en) RGD BONDED TO NEUROPEPTIDES (ARG-GLY-ASP)
ATE449847T1 (en) HEPATITIS C RECEPTOR PROTEIN CD81
ATE444081T1 (en) PROTEINS RELEASE THROUGH POLAR EPITHELIAL CELL LAYER
ATE425770T1 (en) CONTRAST AGENTS

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20131031